UnitedHealth Group Inc

UNH-N

NYSE:UNH

305.35
0.96 (0.31%)
UnitedHealth Group Inc. is an American for profit managed health care company based in Minnetonka, Minnesota. It is sixth in the United States on the Fortune 500.
More at Wikipedia

Analysis and Opinions about UNH-N

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
January 30, 2020
(A Top Pick Jan 23/19, Up 7%) Things will get dicey if Democrats move up, and health care stocks will come off. 13-15% growth rate. Modest dividend. 48 consecutive quarters, 10 years, of consecutive earnings beats. Long-term, a great stock. Fundamentally, a great company.
Show full opinionHide full opinion
(A Top Pick Jan 23/19, Up 7%) Things will get dicey if Democrats move up, and health care stocks will come off. 13-15% growth rate. Modest dividend. 48 consecutive quarters, 10 years, of consecutive earnings beats. Long-term, a great stock. Fundamentally, a great company.
TOP PICK
TOP PICK
January 20, 2020
A big health insurer in America, growing 15% annually with dividend growth. It's been held back because of concerns over whether US healthcare coverage will be reformed by politicians. But the health system there is so massive, it'll be hard to change. UNH is so dominant, it'll grow 10-12% annually with technology to help. (Analysts’ price target is $335.74)
Show full opinionHide full opinion
A big health insurer in America, growing 15% annually with dividend growth. It's been held back because of concerns over whether US healthcare coverage will be reformed by politicians. But the health system there is so massive, it'll be hard to change. UNH is so dominant, it'll grow 10-12% annually with technology to help. (Analysts’ price target is $335.74)
TOP PICK
TOP PICK
January 17, 2020
It offers diversity in an area that the Canadian market doesn't have. Healthcare, insurance, but also owning networks and pharmacy benefit managers. Trades at an attractive multiple for their growth potential. A dominant player that merits the premium. (Analysts’ price target is $335.74)
Show full opinionHide full opinion
It offers diversity in an area that the Canadian market doesn't have. Healthcare, insurance, but also owning networks and pharmacy benefit managers. Trades at an attractive multiple for their growth potential. A dominant player that merits the premium. (Analysts’ price target is $335.74)
PAST TOP PICK
PAST TOP PICK
January 17, 2020
(A Top Pick Dec 03/18, Up 6%) It hasn't been an easy 6%. They have been trading out their covered calls. In early 2019, medicare talks put pressure on this stock. It's a medical insurer, which is a sort of company we don't have in Canada. They deal with healthcare insurance and pharmacy benefit manager. One of the best in the sector.
Show full opinionHide full opinion
(A Top Pick Dec 03/18, Up 6%) It hasn't been an easy 6%. They have been trading out their covered calls. In early 2019, medicare talks put pressure on this stock. It's a medical insurer, which is a sort of company we don't have in Canada. They deal with healthcare insurance and pharmacy benefit manager. One of the best in the sector.
WAIT
WAIT
January 13, 2020
We'll see a lot of heat against the US healthcare space during the campaign this year. Over 10 years, this chart is great, but he would wait until the US election is over before considering any health stock.
Show full opinionHide full opinion
We'll see a lot of heat against the US healthcare space during the campaign this year. Over 10 years, this chart is great, but he would wait until the US election is over before considering any health stock.
COMMENT
COMMENT
December 20, 2019

His choice in this space is Anthem, as it has better valuation metrics (13 times PE versus 17 with UnitedHealth).

Show full opinionHide full opinion

His choice in this space is Anthem, as it has better valuation metrics (13 times PE versus 17 with UnitedHealth).

BUY
BUY
October 24, 2019
US noise has made healthcare names struggle. Well valued. Price has been flat. Recently went above 200-day moving average. Closer to election, investors will realize value in these names. Trading at 15x, with 13% growth rate. Dividend is 1.77%.
Show full opinionHide full opinion
US noise has made healthcare names struggle. Well valued. Price has been flat. Recently went above 200-day moving average. Closer to election, investors will realize value in these names. Trading at 15x, with 13% growth rate. Dividend is 1.77%.
PARTIAL BUY
PARTIAL BUY
October 8, 2019
Always happens in a US election cycle with candidates threatening to restrict health pricing, but this time investors are overreacting. UNH is a good buy. He'll buy it if there is a positive trend in this. Start building a position now.
Show full opinionHide full opinion
Always happens in a US election cycle with candidates threatening to restrict health pricing, but this time investors are overreacting. UNH is a good buy. He'll buy it if there is a positive trend in this. Start building a position now.
DON'T BUY
DON'T BUY
October 3, 2019
He is hesitant to engage in themes that get politicized. Drug pricing can get highly politicized at various points in time. He just avoids it. He backs away. It is a long way to the election. Your risk is way more than your reward. Management is exceptional in this company but it is not worth stepping into this when you cannot handicap the political risk.
Show full opinionHide full opinion
He is hesitant to engage in themes that get politicized. Drug pricing can get highly politicized at various points in time. He just avoids it. He backs away. It is a long way to the election. Your risk is way more than your reward. Management is exceptional in this company but it is not worth stepping into this when you cannot handicap the political risk.
PAST TOP PICK
PAST TOP PICK
September 6, 2019
(A Top Pick Jul 09/19, Down 7%) It’s a longer term hedge, so would still own it. It’s come off more than it should have. The stock is worth $25 higher than where it’s at now.
Show full opinionHide full opinion
(A Top Pick Jul 09/19, Down 7%) It’s a longer term hedge, so would still own it. It’s come off more than it should have. The stock is worth $25 higher than where it’s at now.
BUY
BUY
September 3, 2019
Be ready for a lot of political noise leading up to the US election in Nov. 2020. UNH is a fantastic company. 170 million American hold private insurance through their employers. No, not all Americans, but they have coverage. UNH is well-positioned in health insurance.
Show full opinionHide full opinion
Be ready for a lot of political noise leading up to the US election in Nov. 2020. UNH is a fantastic company. 170 million American hold private insurance through their employers. No, not all Americans, but they have coverage. UNH is well-positioned in health insurance.
WATCH
WATCH
August 2, 2019
Owned it for five years until early this year, because of the noise of "medicare for all" that won't end until a Democratic candidate is chosen. An excellent company, but not timely.
Show full opinionHide full opinion
Owned it for five years until early this year, because of the noise of "medicare for all" that won't end until a Democratic candidate is chosen. An excellent company, but not timely.
TOP PICK
TOP PICK
July 17, 2019
They report tomorrow. UnitedHealth the largest health insurer in the U.S. It has diversified operations. They acquired of pharmacy benefits manager, Catamaran, that'll give them competitive positioning. No matter who wins the next U.S. election, U.S. healthcare will still need UNH's business. (Analysts’ price target is $291.44)
Show full opinionHide full opinion
They report tomorrow. UnitedHealth the largest health insurer in the U.S. It has diversified operations. They acquired of pharmacy benefits manager, Catamaran, that'll give them competitive positioning. No matter who wins the next U.S. election, U.S. healthcare will still need UNH's business. (Analysts’ price target is $291.44)
TOP PICK
TOP PICK
July 9, 2019
Names like this take time and are very volatile. It's weathered the storm and now spending time around $2.30. It's ready to go back up with strong momentum perhaps over 5 weeks. (Analysts’ price target is $288.52)
Show full opinionHide full opinion
Names like this take time and are very volatile. It's weathered the storm and now spending time around $2.30. It's ready to go back up with strong momentum perhaps over 5 weeks. (Analysts’ price target is $288.52)
TOP PICK
TOP PICK
July 4, 2019
The US is talking about having Medicare for all. This company does a good job of eliminating cost for all involved. They raised the dividend over the last few years. He sees it as a good solid company. (Analysts’ price target is $287.80)
Show full opinionHide full opinion
The US is talking about having Medicare for all. This company does a good job of eliminating cost for all involved. They raised the dividend over the last few years. He sees it as a good solid company. (Analysts’ price target is $287.80)
PAST TOP PICK
PAST TOP PICK
May 24, 2019
(A Top Pick Mar 11/19, Up 2%) Really good day trade. Not a happy place to be as a retail investor. Not something you need to own right away. Chart's gone straight up for so long, but now facing some turbulence. Now it's a hold or a watch.
Show full opinionHide full opinion
(A Top Pick Mar 11/19, Up 2%) Really good day trade. Not a happy place to be as a retail investor. Not something you need to own right away. Chart's gone straight up for so long, but now facing some turbulence. Now it's a hold or a watch.
TOP PICK
TOP PICK
May 23, 2019
They are the largest Health Care provider in the US. He thinks it is going back into the $300 territory after the election. P/E is 17. (Analysts’ price target is $287.72)
Show full opinionHide full opinion
They are the largest Health Care provider in the US. He thinks it is going back into the $300 territory after the election. P/E is 17. (Analysts’ price target is $287.72)
DON'T BUY
DON'T BUY
May 13, 2019
Basically an insurance provider. Healthcare space in general is messy. Trump is attacking healthcare companies. Insurance costs are rising, but they can't keep going up when wages aren't increasing. So insurance is trying to move down the food chain. Plus, Amazon is getting into the business. He'd be really nervous.
Show full opinionHide full opinion
Basically an insurance provider. Healthcare space in general is messy. Trump is attacking healthcare companies. Insurance costs are rising, but they can't keep going up when wages aren't increasing. So insurance is trying to move down the food chain. Plus, Amazon is getting into the business. He'd be really nervous.
TOP PICK
TOP PICK
May 3, 2019
A managed care company. Like a large medical insurance company, but they own their own facilities and networks. A shock when it sold off. Valuation is fantastic. Once in a decade buying opportunity. Yield is 1.55%. (Analysts’ price target is $288.54)
Show full opinionHide full opinion
A managed care company. Like a large medical insurance company, but they own their own facilities and networks. A shock when it sold off. Valuation is fantastic. Once in a decade buying opportunity. Yield is 1.55%. (Analysts’ price target is $288.54)
BUY
BUY
April 4, 2019
Trading at 17 times forward earnings. 13-14% growth rate. 1.5% dividend yield. 15 billion dollar worth of free cash flow. They are in pharmacy and benefit management service. They are have scale across different segments. Good for an uncertain time despite the politics.
Show full opinionHide full opinion
Trading at 17 times forward earnings. 13-14% growth rate. 1.5% dividend yield. 15 billion dollar worth of free cash flow. They are in pharmacy and benefit management service. They are have scale across different segments. Good for an uncertain time despite the politics.
BUY WEAKNESS
BUY WEAKNESS
April 2, 2019
Good operator. Sensible balance sheet. Like the "Home Depot" of healthcare. Difficult to buy on price. Well run. Always at a premium price, as it's a good company.
Show full opinionHide full opinion
Good operator. Sensible balance sheet. Like the "Home Depot" of healthcare. Difficult to buy on price. Well run. Always at a premium price, as it's a good company.
TOP PICK
TOP PICK
March 11, 2019
Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.
Show full opinionHide full opinion
Just tested the 50- and 100-week moving averages--and hasn't broken them. It's still cheap after selling off, building a base and is now moving up.
WAIT
WAIT
March 6, 2019
Start a position at $240? Positives: top-shelf management with a history of returning 50% of free cash flow each year through dividends and stock buys. They're massive and have cost advantage. Cons: in consolidation now. He takes a longer view on UNH, but wouldn't buy it now. There's no rush to. UNH is also beta. Numbers solid, but UNH isn't cheap. Watch it.
Show full opinionHide full opinion
Start a position at $240? Positives: top-shelf management with a history of returning 50% of free cash flow each year through dividends and stock buys. They're massive and have cost advantage. Cons: in consolidation now. He takes a longer view on UNH, but wouldn't buy it now. There's no rush to. UNH is also beta. Numbers solid, but UNH isn't cheap. Watch it.
BUY
BUY
February 7, 2019
On a 12 months basis it is better than 85% of the companies in the NYSE. Healthcare has come back quite nicely. This is trading well above a rising 150 day average. This is a theme you can depend on. Managed Healthcare. Continue to hold it.
Show full opinionHide full opinion
On a 12 months basis it is better than 85% of the companies in the NYSE. Healthcare has come back quite nicely. This is trading well above a rising 150 day average. This is a theme you can depend on. Managed Healthcare. Continue to hold it.
BUY WEAKNESS
BUY WEAKNESS
January 31, 2019
It has characteristics of a defensive nature but grows at double digit earnings each year. There are headwinds in that space. Amazon may be entering the pharmacy business. But people are living longer and will need health care longer. Buy it on dips.
Show full opinionHide full opinion
It has characteristics of a defensive nature but grows at double digit earnings each year. There are headwinds in that space. Amazon may be entering the pharmacy business. But people are living longer and will need health care longer. Buy it on dips.
COMMENT
COMMENT
January 23, 2019
18X foward earnings. ROE is 20% average over 5 five years. Healthcare gies you (Analysts’ price target is $301.58)
Show full opinionHide full opinion
18X foward earnings. ROE is 20% average over 5 five years. Healthcare gies you (Analysts’ price target is $301.58)
TOP PICK
TOP PICK
December 11, 2018
It's #5 in revenue of all US companies. They'll do $250 billion in revenue in 2019. It's down only 7-8% during this market carngage, so it's held its own. The CEO belives they just started a growth boom. Has a good runway ahead, working closely with government agencies and in South America. Good defensive stock. (Analysts’ price target is $304.74)
Show full opinionHide full opinion
It's #5 in revenue of all US companies. They'll do $250 billion in revenue in 2019. It's down only 7-8% during this market carngage, so it's held its own. The CEO belives they just started a growth boom. Has a good runway ahead, working closely with government agencies and in South America. Good defensive stock. (Analysts’ price target is $304.74)
WATCH
WATCH
December 6, 2018
They are just so consistent. The health care sector is just so influenced by politics. But these guys reduce costs for governments. This stock has been spectacular. They have scale and a phenomenal management team that returns capital to shareholders. He would not buy more at this time.
Show full opinionHide full opinion
They are just so consistent. The health care sector is just so influenced by politics. But these guys reduce costs for governments. This stock has been spectacular. They have scale and a phenomenal management team that returns capital to shareholders. He would not buy more at this time.
BUY
BUY
December 6, 2018
Looks very strong. The technical strength is strong. PEG ratio is 1.4. Likes it. Longer term, 1 year, 24 months this is a good place to be.
Show full opinionHide full opinion
Looks very strong. The technical strength is strong. PEG ratio is 1.4. Likes it. Longer term, 1 year, 24 months this is a good place to be.
TOP PICK
TOP PICK
December 3, 2018
They've had a great run and are the poster child of the U.S. health insurance space. They continue to put up 15% bottom-line growth. (Analysts’ price target is $304.74)
Show full opinionHide full opinion
They've had a great run and are the poster child of the U.S. health insurance space. They continue to put up 15% bottom-line growth. (Analysts’ price target is $304.74)
TOP PICK
TOP PICK
November 12, 2018
Healthcare is a fantastic bull market. They have a great chart, in atrong uptrend since 2014 with higher highs and higher lows. (Analysts’ price target is $300.87)
Show full opinionHide full opinion
Healthcare is a fantastic bull market. They have a great chart, in atrong uptrend since 2014 with higher highs and higher lows. (Analysts’ price target is $300.87)
BUY
BUY
November 9, 2018
They have very good management. Very strong on momentum and most of the technicals. It is one of his top picks. One of his top picks in the sector. Buy on the dip if possible.
Show full opinionHide full opinion
They have very good management. Very strong on momentum and most of the technicals. It is one of his top picks. One of his top picks in the sector. Buy on the dip if possible.
HOLD
HOLD
October 17, 2018

The company came out with very strong earnings – 12% growth y-o-y. Despite the run in share prices currently, he thinks there is still lots of runway. The companies touches on so many aspects of public health in the US and suggests politicians will avoid public cuts in spending going forward. He sees their growth continuing. Yield 1.3%.

Show full opinionHide full opinion

The company came out with very strong earnings – 12% growth y-o-y. Despite the run in share prices currently, he thinks there is still lots of runway. The companies touches on so many aspects of public health in the US and suggests politicians will avoid public cuts in spending going forward. He sees their growth continuing. Yield 1.3%.

BUY
BUY
August 21, 2018

This is a very positive company. This is a large US insurer, with a separate interest in health records and technology. The company has done very well but still trades at a reasonable valuation.

Show full opinionHide full opinion

This is a very positive company. This is a large US insurer, with a separate interest in health records and technology. The company has done very well but still trades at a reasonable valuation.

HOLD
HOLD
August 20, 2018

Its technicals and fundamentals have nicely converged and is now perfectly priced. There's no upside or downside here. No momentum to rise. Maybe in another year there'll be enough earnings.

Show full opinionHide full opinion

Its technicals and fundamentals have nicely converged and is now perfectly priced. There's no upside or downside here. No momentum to rise. Maybe in another year there'll be enough earnings.

TOP PICK
TOP PICK
August 13, 2018

Healthcare is in a secular bull market. Fantastsic trend upwards over the past year. Executing well. (Analysts' price target: $280.23)

Show full opinionHide full opinion

Healthcare is in a secular bull market. Fantastsic trend upwards over the past year. Executing well. (Analysts' price target: $280.23)

PAST TOP PICK
PAST TOP PICK
July 5, 2018

(A Top Pick September 14/17 - Up 27%.) A tremendous growth story. Still a holding. Dominant leaders in the space.

Show full opinionHide full opinion

(A Top Pick September 14/17 - Up 27%.) A tremendous growth story. Still a holding. Dominant leaders in the space.

PAST TOP PICK
PAST TOP PICK
May 9, 2018

(A Top Pick June 13/17 Up 29%) He sees no reason to move away from this holding. It is a consistent performer and will continue to do well. The independant gorilla in the Medicare and Medicaid space in the US. Did have a little bit of a pullback and consolidation. A very positive story and good momentum based on last quarter earnings.

Show full opinionHide full opinion

(A Top Pick June 13/17 Up 29%) He sees no reason to move away from this holding. It is a consistent performer and will continue to do well. The independant gorilla in the Medicare and Medicaid space in the US. Did have a little bit of a pullback and consolidation. A very positive story and good momentum based on last quarter earnings.

PAST TOP PICK
PAST TOP PICK
March 21, 2018

(A Top Pick May 10/17, Up 30%) Pure health insurance in the U.S. and expects it be the dominant player. Made a tremendous acquisition 2012 that's paid off. Stock is a great performer, and he likes the sector, too, which will consolidate.

Show full opinionHide full opinion

(A Top Pick May 10/17, Up 30%) Pure health insurance in the U.S. and expects it be the dominant player. Made a tremendous acquisition 2012 that's paid off. Stock is a great performer, and he likes the sector, too, which will consolidate.

COMMENT
COMMENT
January 30, 2018

Amazon, Berkshire Hathaway and J.P. Morgan just announced forming a healthcare company aimed at cutting costs. The experiment with government led healthcare mandates really didn’t work. There was far too much friction between opposing views. If you own the stock, you shouldn't get too excited about just one day, or the fact that insurers are going to go away.

Show full opinionHide full opinion

Amazon, Berkshire Hathaway and J.P. Morgan just announced forming a healthcare company aimed at cutting costs. The experiment with government led healthcare mandates really didn’t work. There was far too much friction between opposing views. If you own the stock, you shouldn't get too excited about just one day, or the fact that insurers are going to go away.